CollPlant shares surge 10.16% intraday as company targets GLP-1-driven aesthetic market with new dermal filler platform.

CollPlant surged 10.16% intraday trading after announcing its strategic pivot to leverage the GLP-1-driven aesthetic market with a photocurable rhCollagen-based dermal filler platform targeting facial volume loss. The move positions the company to capitalize on growing demand for biotech-enabled cosmetic solutions, aligning with broader industry trends in regenerative medicine and aesthetics. The announcement reflects a clear expansion strategy, emphasizing innovation in collagen-based applications, which could attract investor confidence in the firm’s long-term growth potential.